Clinical trial • Phase I • Cardiology
BAY 3620122 for Vasodilatory shock
Phase I trial of BAY 3620122 for Vasodilatory shock. 190 participants.
Overview
- Trial Therapeutic Area
- Cardiology
- Trial Disease
- Vasodilatory shock
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 11-09-2025
- First CTIS Authorization Date
- 11-11-2025
Trial design
Phase I trial across 1 site in Germany.
- Target Sample Size
- 190
Recruitment
- Planned Sample Size
- 190
- Recruitment Window Months
- 11
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 190
Germany
- Earliest CTIS Part Ii Submission Date
- 05-11-2025
- Latest Decision Or Authorization Date
- 05-03-2026
- Processing Time Days
- 120
- Number Of Sites
- 1
- Number Of Participants
- 190
Sites
- Site Name
- Nuvisan GmbH
- Department Name
- Clinical Operations
- Contact Person Name
- Steffen Haffner
- Contact Person Email
- Steffen.Haffner@nuvisan.com
- Number Of Participants
- 190
Sponsor
Primary sponsor
- Full Name
- Bayer AG
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- BAY 3620122
- First In Human
- Yes
Related trials
Other published trials that may interest you.
- METHYLPREDNISOLONE for Fulminant myocarditis
- PELACARSEN for Cardiovascular disease | Arteriosclerotic cardiovascular disease
- clopidogrel for Acute coronary syndrome | Cardiovascular diseases
- APIXABAN for Venous thromboembolism
- SOTAGLIFLOZIN for Obstructive hypertrophic cardiomyopathy | Non-obstructive hypertrophic cardiomyopathy